

# Global CD19 Antibody Market & Clinical Pipeline Outlook 2028

<https://marketpublishers.com/r/GF3EA8577D04EN.html>

Date: October 2023

Pages: 420

Price: US\$ 2,900.00 (Single User License)

ID: GF3EA8577D04EN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global CD19 Antibody Market & Clinical Pipeline Outlook 2028 Report Highlights:

Global CD19 Antibody Market Opportunity: > USD 10 Billion By 2028

Commercially Approved CD19 Antibodies: 10 Antibodies

Annual, Quarterly & Regional Sales Insight On Approved CD19 Antibodies

Dosage & Price Insight On Approved CD19 Antibodies

Comprehensive Insights On CD19 Antibodies In Clinical Trials: > 190 Antibodies

Global CD19 Antibodies Clinical Trials By Company, Indication & Phase

Competitive Landscape: Insight On 30 companies

CD19 targeting therapies have emerged as another revolutionary class of immunotherapies in the past decade. These therapies, which consist of monoclonal antibodies, a bispecific antibody, an antibody-drug conjugate and chimeric antigen receptor T-cell (CAR-T) therapies, have captured the attention of both the clinical and commercial spheres in the global pharmaceutical industry. The patient and physician response to these therapies has been favorable as well, which can be gathered from the fact that the market of CD19-targeting therapies increased by almost 50% in 2021,

and 40% in 2022. This can be attributed to the rapid regulatory approvals, and the current pipeline of investigational CD19-targeting therapies shows potential for a further surge of this market cap.

CD19-targeting therapies have made a significant impact on the clinical landscape of cancer treatment. They are primarily used for treating B-cell malignancies such as non-Hodgkin lymphoma (NHL) like acute lymphocytic leukemia (ALL), and large B-cell lymphoma (LBCL). The clinical efficacy of these therapies, especially CAR-T therapies like Kymriah and Yescarta, has been remarkable, leading to high response rates and prolonged remissions in a substantial proportion of patients, making them a promising treatment options. However, CAR-T therapies are not without challenges. Cytokine release syndrome (CRS) and neurotoxicity are often associated with CAR-T therapies; however, researchers have found ways to manage these.

Unlike some traditional therapies, CD19-targeting therapies have shown the potential for long-lasting responses. Patients who achieve remission can remain disease-free for extended periods, significantly improving their quality of life. Moreover, CD19-targeting therapies also represent a big step towards personalized medicine. They are tailored to each patient's unique immune system and the characteristics of their cancer cells, making them a highly individualized treatment.

CD19-targeting therapies have also become a focal point for pharmaceutical companies. The pharmaceutical industry has seen intense competition in the development and commercialization of CD19-targeting therapies. Established giants like Novartis, Amgen, and Gilead have played a significant role but smaller biotech firms are also entering the market now, bringing with them innovative treatments. An example of this is Uplizna, which was developed by Viela Bio, though now a part of Amgen.

At present, nine CD19-targeting therapies have received approval from the regulatory bodies. These are the bispecific antibody Blincyto, the monoclonal antibodies Uplizna and Monjuvi, the antibody-drug conjugate Zynlonta, and the CAR-T therapies Kymriah, Yescarta, Tecartus, Breyanzi, and Carteyva. While the first eight have FDA approvals, Carteyva only has a regional approval in China, where JW Therapeutics markets it.

The continued success of these therapies in the market has been encouraging for the research and development sector of the pharmaceutical market, and as a result, several new CD19-targeting therapies have entered the development and clinical trial pipelines. A majority of these are CD19-targeting CAR-T therapies, which are being developed for hematological cancers such as acute lymphocytic leukemia (ALL) and chronic

lymphocytic leukemia (CLL) among other non-Hodgkin lymphomas. This is closely followed by disorders of the immune system, such as autoimmune diseases like systemic lupus erythematosus (SLE) Sjogren's syndrome and systemic scleroderma.

The regulatory bodies have also been instrumental in encouraging the development of CD19-targeting therapies by granting several of them special drug designations. The FDA, for instance, granted the Fast Track designation to KYV-101, IMPT-314 and CABA-201, which have been developed by Kyverna Therapeutics, ImmPACT Bio' and Cabaletta Bio, respectively. In addition, the FDA also accepted the IND applications of many candidates recently, with the newest being Kyverna's KYV-101 for the treatment of diffuse cutaneous systemic sclerosis in October 2023.

The market has also seen some collaborations happening lately for the research and development of innovative CD19-targeting therapies, having characteristics unprecedented by the approved CD19-targeting therapies, which are anticipated to give these an edge in the market upon approval. This includes the use of proprietary platforms to help cut down on the cost and time spent in the development of these therapies.

Thus, the market of CD19-targeting therapies is quite vibrant and dynamic, and is currently being driven by several factors. Moreover, as research finds use of CD19-targeting therapies in newer indications, it is obvious that the therapeutic potential of the CD19 protein remains to be fully uncovered. New market entrants have been increasing the competition within the market, which is expected to be one of the major factors driving innovation at present.

## Contents

### **1. RESEARCH METHODOLOGY**

### **2. APPROVED CD19 TARGETING THERAPIES**

### **3. GLOBAL CD19 ANTIBODIES MARKET DYNAMICS**

3.1 Current Market Trends & Developments

3.2 Future Growth Avenues

### **4. CD19 TARGETING THERAPIES CLINICAL TRIALS & MARKET INSIGHT BY INDICATION**

4.1 Hematological Cancers

4.1.1 Leukemia

4.1.2 Lymphoma

4.2 Solid Cancers

4.3 Immune System Diseases

### **5. CD19 TARGETING THERAPIES MARKET DYNAMICS BY REGION**

5.1 US

5.2 China

5.3 EU

5.4 Canada

5.5 Australia

### **6. GLOBAL CD19 MARKET SALES & PRICE INSIGHT BY APPROVED DRUGS**

6.1 Blincyto - 1st CD19 Targeting Therapy

6.1.1 Overview & Patent Insight

6.1.2 Pricing & Dosage Insight

6.1.3 Sales Analysis

6.2 Kymriah - 1st Anti-CD19 CAR T Cell Therapy

6.2.1 Overview

6.2.2 Pricing & Dosage Insight

### 6.2.3 Sales Analysis

## 6.3 Yescarta

### 6.3.1 Overview & Patent Insight

### 6.3.2 Pricing & Dosage

### 6.3.3 Sales Analysis

## 6.4 Uplizna - 1st Anti-CD19 Monoclonal Antibody

### 6.4.1 Overview & Patent Insight

### 6.4.2 Pricing & Dosage

### 6.4.3 Sales Analysis

## 6.5 Tecartus

### 6.5.1 Overview

### 6.5.2 Pricing & Dosage

### 6.5.3 Sales Analysis

## 6.6 Monjuvi

### 6.6.1 Overview & Patent Insight

### 6.6.2 Pricing & Dosage

### 6.6.3 Sales Analysis

## 6.7 Breyanzi

### 6.7.1 Overview & Patent Insight

### 6.7.2 Pricing & Dosage

### 6.7.3 Sales Analysis

## 6.8 Zynlonta - 1st CD19-Targeted ADC Therapy

### 6.8.1 Overview & Patent Insight

### 6.8.2 Pricing & Dosage

### 6.8.3 Sales Analysis

## 6.9 Carteyva

### 6.9.1 Overview & Patent Insight

### 6.9.2 Sales Analysis

## 6.10 NexCAR19 - 1st CD19 Targeting CAR T Cell Therapy

# 7. GLOBAL CD19 ANTIBODIES CLINICAL TRIALS OVERVIEW

## 7.1 By Country

## 7.2 Indication

## 7.3 Phase

## 7.4 Therapy Class

# 8. GLOBAL CD19 ANTIBODIES CLINICAL TRIALS BY COMPANY, INDICATION & PHASE

- 8.1 Research
- 8.2 Preclinical
- 8.3 Phase-I
- 8.4 Phase-I/II
- 8.5 Phase-II
- 8.6 Phase-III
- 8.7 Preregistration
- 8.8 Registered

## **9. COMMERCIALY APPROVED CD19 ANTIBODIES CLINICAL INSIGHT**

## **10. COMPETITIVE LANDSCAPE**

- 10.1 AbbVie
- 10.2 Aleta Biotherapeutics
- 10.3 Autolus
- 10.4 Bristol-Myers Squibb
- 10.5 Cabaret Biotech
- 10.6 Cellectis
- 10.7 Cellular Biomedicine Group
- 10.8 Chongqing Precision Biotech Co., Ltd
- 10.9 CRISPR Therapeutics
- 10.10 Eureka Therapeutics
- 10.11 EXUMA Biotech
- 10.12 Fate Therapeutics
- 10.13 Galapagos NV
- 10.14 Gilead Sciences
- 10.15 Gracell Biotechnology
- 10.16 Guangzhou Bio-gene Technology
- 10.17 Hebei Senlang Biotechnology
- 10.18 ImmPACT Bio
- 10.19 Immvira Pharma
- 10.20 Innovative Cellular Therapeutics
- 10.21 Juventas Cell Therapy
- 10.22 Kite Pharma
- 10.23 Kyverna Therapeutics
- 10.24 MedTherapy

10.25 Memorial Sloan-Kettering Cancer Center

10.26 Nanjing Bioheng Biotech

10.27 Nanjing IASO Biotherapeutics

10.28 Poseida Therapeutics

10.29 Precision Biosciences

10.30 Sana Biotechnology

Table 2-1: Globally Approved CD19 Targeting Therapies

Table 3-1: Global – CD19 Antibodies Sales By Brand Name (US\$ Million), 2019-2023

Table 3-2: Global – CD19 Antibodies Quarterly Sales (US\$ Million), 2022

Table 4-1: Hematological Cancers - Approved CD19 Targeting Therapies & Mechanism of Action

Table 4-2: Immune System Diseases - Approved CD19 targeting therapies & Mechanism of Action

Table 5-1: US – FDA Designations for CD19 Targeting Therapies, October'2023

Table 5-2: US – FDA IND Applications Accepted for CD19 Targeting Therapies, October'2023

Table 5-3: China – NMPA IND Applications Accepted for CD19 Targeting Therapies, October'2023

Table 6-1: Blincyto - Recommended Dosage & Schedule for the Treatment of MRD-positive B-cell Precursor ALL

Table 6-2: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL

Table 6-3: Blincyto – Recommended Dose Modifications

Table 6-4: Uplizna - Premedication Prior to Each Infusion

Table 6-5: Monjuvi - Dosing Schedule

Table 6-6: Monjuvi - Dosage Modifications for Adverse Reactions

## List Of Figures

### LIST OF FIGURES

Figure 3-1: Global – CD19 Antibodies Sales (US\$ Million), 2019-2023  
Figure 3-2: Global – CD19 Antibodies Sales by Brand Name (US\$ Million), H1'2023  
Figure 3-3: Global – CD19 Antibodies Quarterly Sales (US\$ Million), 2023  
Figure 3-4: Global – CD19 Antibodies Sales by Brand Name (US\$ Million), 2022  
Figure 3-5: Global – CD19 Antibodies Quarterly Sales (US\$ Million), 2022  
Figure 3-6: Global – CD19 Antibodies Sales (US\$ Million), 2022 - 2028  
Figure 4-1: CD19 Expression in B-Cell Malignancies (%)  
Figure 4-2: Leukemia – Global CD19 Targeting Therapies Sales Values (US\$ Million),

### 2021-2023

Figure 4-3: NCT05020392 Phase III Study – Initiation & Completion Years  
Figure 4-4: NCT05020392 Phase III Study – Initiation & Completion Years  
Figure 4-5: OSU-13031 Phase II Study – Initiation & Completion Years  
Figure 4-6: BIM-HEM-I Phase II Study – Initiation & Completion Years  
Figure 4-7: Lymphoma – Global CD19 Targeting Therapies Sales Values (US\$ Million),

### 2021-2023

Figure 4-8: IKS03-01 Phase I Study – Initiation & Completion Years  
Figure 4-9: NCT05149391 Phase I Study – Initiation & Completion Years  
Figure 4-10: MPCT-012L Phase I/II Study – Initiation & Completion Years  
Figure 4-11: NCT05583149 Phase II Study – Initiation & Completion Years  
Figure 4-12: NKX019-101 Phase I Study – Initiation & Completion Years  
Figure 4-13: MOR208C310 Phase III Study – Initiation & Completion Years  
Figure 4-14: TG-1801-102 Phase I Study – Initiation & Completion Years  
Figure 4-15: CF33-CD19 - Combination of CF33 OV & CAR T Cell Therapy  
Figure 4-16: CF33-CD19-101 Phase I Study – Initiation & Completion Years  
Figure 4-17: STRIVE-01 Phase I Study – Initiation & Completion Years  
Figure 4-18: STRIVE-02 Phase I Study – Initiation & Completion Years  
Figure 4-19: Inebilizumab – Proposed Mechanism of Action  
Figure 4-20: NCT05549258 Phase II Study – Initiation & Completion Years  
Figure 4-21: ExTINGUISH Phase II Study – Initiation & Completion Years  
Figure 4-22: NCT04524273 Phase III Study – Initiation & Completion Years  
Figure 4-23: INDIGO Phase III Study – Initiation & Completion Years



- Figure 4-24: SApHiAre Phase III Study – Initiation & Completion Years
- Figure 4-25: CD19/BCMA-003 Phase I Study – Initiation & Completion Years
- Figure 4-26: CD19/BCMA-002 Phase I Study – Initiation & Completion Years
- Figure 4-27: JWCAR029012 Phase I Study – Initiation & Completion Years
- Figure 5-1: US – Approval Years of CD19 Targeting Therapies
- Figure 5-2: US – Blincyto Patent Filing & Expiration Years
- Figure 5-3: China – Approval Years of CD19 Targeting Therapies
- Figure 5-4: EU – Approval Years of CD19 Targeting Therapies
- Figure 5-5: Canada – Approval Years of CD19 Targeting Therapies
- Figure 5-6: Canada – Blincyto Patents Approval & Expiration Years
- Figure 5-7: Canada – Kymriah Patents Approval & Expiration Years
- Figure 5-8: Australia – Approval Years of CD19 Targeting Therapies
- Figure 6-1: Blincyto – Approval Years by Region
- Figure 6-2: Blincyto – US Patent Acceptance & Expiration Years
- Figure 6-3: Blincyto – EU Patent Expiration Years
- Figure 6-4: US - Cost Of Single Blincyto Supply (US\$), October'2023
- Figure 6-5: Blincyto – Treatment Course of MRD-Positive B-cell precursor ALL
- Figure 6-6: Blincyto – Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD-Positive B-cell precursor (Days)
- Figure 6-7: Blincyto - Cost of Single Cycle & Treatment Course for the Treatment of MRD-positive B-cell Precursor ALL
- Figure 6-8: Blincyto – Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL
- Figure 6-9: Blincyto – Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)
- Figure 6-10: Blincyto - Cost of Single Cycle & Treatment Course for Treatment for Relapsed B-Cell Precursor ALL
- Figure 6-11: Global – Blincyto Annual Sales Value (US\$ Million), 2019-2023
- Figure 6-12: US – Blincyto Annual Sales Value (US\$ Million), 2019-2023
- Figure 6-13: ROW – Blincyto Annual Sales Value (US\$ Million), 2019-2023
- Figure 6-14: Global – Blincyto Quarterly Sales Value (US\$ Million), 2023
- Figure 6-15: US – Blincyto Quarterly Sales Value (US\$ Million), 2023
- Figure 6-16: ROW – Blincyto Quarterly Sales Value (US\$ Million), 2023
- Figure 6-17: Global – Blincyto Quarterly Sales Value (US\$ Million), 2022
- Figure 6-18: US – Blincyto Quarterly Sales Value (US\$ Million), 2022
- Figure 6-19: ROW – Blincyto Quarterly Sales Value (US\$ Million), 2022
- Figure 6-20: US – Kymriah Approval Years by Indications
- Figure 6-21: Kymriah – Approval Years by Region
- Figure 6-22: US - Kymriah Suspension Cost (US\$), October'2023

- Figure 6-23: Global – Kymriah Annual Sales Value (US\$ Million), 2019-2023
- Figure 6-24: Global - Kymriah Quarterly Sales Value (US\$ Million), 2023
- Figure 6-25: Global – Kymriah Quarterly Sales Value (US\$ Million), 2022
- Figure 6-26: US - Kymriah Quarterly Sales Value (US\$ Million), 2022
- Figure 6-27: ROW - Kymriah Quarterly Sales Value (US\$ Million), 2022
- Figure 6-28: US – Yescarta Approval Years by Indications
- Figure 6-29: Yescarta – Approval Years by Region
- Figure 6-30: Yescarta – US Patent Approval & Expiration Year
- Figure 6-31: US - Yescarta List Price (US\$), October'2023
- Figure 6-32: Global – Yescarta Annual Sales Value (US\$ Million), 2019-2023
- Figure 6-33: US – Yescarta Annual Sales Value (US\$ Million), 2019-2023
- Figure 6-34: EU – Yescarta Annual Sales Value (US\$ Million), 2019-2023
- Figure 6-35: ROW – Yescarta Annual Sales Value (US\$ Million), 2019-2023
- Figure 6-36: Global – Yescarta Quarterly Sales Value (US\$ Million), 2023
- Figure 6-37: US – Yescarta Quarterly Sales Value (US\$ Million), 2023
- Figure 6-38: EU – Yescarta Quarterly Sales Value (US\$ Million), 2023
- Figure 6-39: ROW – Yescarta Quarterly Sales Value (US\$ Million), 2023
- Figure 6-40: Global – Yescarta Quarterly Sales Value (US\$ Million), 2022
- Figure 6-41: US – Yescarta Quarterly Sales Value (US\$ Million), 2022
- Figure 6-42: EU – Yescarta Quarterly Sales Value (US\$ Million), 2022
- Figure 6-43: ROW – Yescarta Quarterly Sales Value (US\$ Million), 2022
- Figure 6-44: Uplizna – Approval Years by Region
- Figure 6-45: US - Unit & Supply Cost of Uplizna (US\$), October'2023
- Figure 6-46: Global - Uplizna Annual Sales Value (US\$), 2021-2023
- Figure 6-47: Global - Uplizna Quarterly Sales Value (US\$ Million), 2023
- Figure 6-48: Global – Uplizna Quarterly Sales Value (US\$ Million), 2022
- Figure 6-49: US – Tecartus Approval Years by Indications
- Figure 6-50: Tecartus – Approval Years by Region
- Figure 6-51: US - Tecartus List Price (US\$), October'2023
- Figure 6-52: Global – Tecartus Annual Sales Value (US\$ Million), 2020-2023
- Figure 6-53: US – Tecartus Annual Sales Value (US\$ Million), 2020-2023
- Figure 6-54: EU – Tecartus Annual Sales Value (US\$ Million), 2020-2023
- Figure 6-55: ROW – Tecartus Annual Sales Value (US\$ Million), 2020-2023
- Figure 6-56: Global – Tecartus Quarterly Sales Value (US\$ Million), 2023
- Figure 6-57: US – Tecartus Quarterly Sales Value (US\$ Million), 2023
- Figure 6-58: EU – Tecartus Quarterly Sales Value (US\$ Million), 2023
- Figure 6-59 ROW – Tecartus Quarterly Sales Value (US\$ Million), 2023
- Figure 6-60: Global – Tecartus Quarterly Sales Value (US\$ Million), 2022
- Figure 6-61: US – Tecartus Quarterly Sales Value (US\$ Million), 2022

- Figure 6-62: EU – Tecartus Quarterly Sales Value (US\$ Million), 2022
- Figure 6-63 ROW – Tecartus Quarterly Sales Value (US\$ Million), 2022
- Figure 6-64: Monjuvi – Approval Years by Region
- Figure 6-65: Monjuvi – Patent Expiry Years by Region
- Figure 6-66: US – Supply Cost of Monjuvi (US\$), October'2023
- Figure 6-67: Global – Monjuvi Annual Sales Value (US\$ Million), 2020-2023
- Figure 6-68: US – Monjuvi Annual Sales Value (US\$ Million), 2020-2023
- Figure 6-69: ROW – Monjuvi Annual Sales Value (US\$ Million), 2020-2023
- Figure 6-70: Global - Monjuvi Quarterly Sales Value (US\$ Million), 2023
- Figure 6-71: US - Monjuvi Quarterly Sales Value (US\$ Million), 2023
- Figure 6-72: ROW - Monjuvi Quarterly Sales Value (US\$ Million), 2023
- Figure 6-73: Global – Monjuvi Quarterly Sales Value (US\$ Million), 2022
- Figure 6-74: US - Monjuvi Quarterly Sales Value (US\$ Million), 2022
- Figure 6-75: ROW - Monjuvi Quarterly Sales Value (US\$ Million), 2022
- Figure 6-76: Breyanzi – Approval Years by Region
- Figure 6-77: Breyanzi – Estimated Minimum Market Exclusivity Years
- Figure 6-78: US – Supply Cost of Breyanzi (US\$), October'2023
- Figure 6-79: Global – Breyanzi Annual Sales Value (US\$ Million), 2021-2023
- Figure 6-80: US – Breyanzi Annual Sales Value (US\$ Million), 2021-2023
- Figure 6-81: ROW – Breyanzi Annual Sales Value (US\$ Million), 2021-2023
- Figure 6-82: Global - Breyanzi Quarterly Sales Value (US\$ Million), 2023
- Figure 6-83: US - Breyanzi Quarterly Sales Value (US\$ Million), 2023
- Figure 6-84: ROW - Breyanzi Quarterly Sales Value (US\$ Million), 2023
- Figure 6-85: Global - Breyanzi Quarterly Sales Value (US\$ Million), 2022
- Figure 6-86: US - Breyanzi Quarterly Sales Value (US\$ Million), 2022
- Figure 6-87: ROW - Breyanzi Quarterly Sales Value (US\$ Million), 2022
- Figure 6-88: Zynlonta – Approval Years by Region
- Figure 6-89: Zynlonta – Recommended Dose for Initial & Subsequent Cycles (mg/kg)
- Figure 6-90: Zynlonta – Single Cycle & Annual Treatment Cost (US\$)
- Figure 6-91: Global – Zynlonta Annual Sales Value (US\$ Million), 2021-2023
- Figure 6-92: Global – Zynlonta Quarterly Sales Value (US\$ Million), 2023
- Figure 6-93: Global – Zynlonta Quarterly Sales Value (US\$ Million), 2022
- Figure 6-94: Carteyva – NMPA Approval Years by Indication
- Figure 6-95: Global – Carteyva Annual Sales Value (US\$ Million), 2021-2023
- Figure 6-96: Global – Carteyva Half-Yearly Sales Values (US\$ Million), 2021-2023
- Figure 7-1: Global - CD19 Antibodies Trials by Country (Numbers), 2023 Till 2028
- Figure 7-2: Global - CD19 Antibodies Trials by Indication (Numbers), 2023 Till 2028
- Figure 7-3: Global - CD19 Antibodies Trials by Phase (Numbers), 2023 Till 2028
- Figure 7-4: Global - CD19 Antibodies Trials by Therapy Class (Numbers), 2023 Till

**2028**

## I would like to order

Product name: Global CD19 Antibody Market & Clinical Pipeline Outlook 2028

Product link: <https://marketpublishers.com/r/GF3EA8577D04EN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF3EA8577D04EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970